Table 1.
Examples of clinical trials of Immune targets in breast cancer immunotherapy.
| Target | Drugs | Company | With combination | Phase | Clinicaltrials.gov identifier (selected trials) |
|---|---|---|---|---|---|
| Anti-(PD-1) | Pembrolizumab | Merck | +Nab-paclitaxel/Paclitaxel/ Gemcitabine/Carboplatin | III | NCT02819518 |
| Anti-(PD-L1) | Atezolizumab | Genentech/Roche | – | I | NCT01375842 |
| + Nab-paclitaxel | III | NCT02425891 | |||
| Avelumab | Merck | – | III | NCT02926196 | |
| Anti-(CTLA-4) | tremelimumab | AstraZeneca | +Exemestane/ durvalumab | II | NCT02997995 |
| + Durvalumab | I/II |
NCT01975831 NCT02536794 |
|||
| Ipilimumab | Bristol-Myers Squibb (BMS) | + Nivolumab/ cobimetinib | I/ II | NCT01928394 | |
| + Enoblituzumab | I | NCT02381314 | |||
| Anti-(LAG-3) | IMP321/Eftilagimod alpha | Immutep | +Paclitaxel | II | NCT02614833 |
| Anti-(TIM-3) | MBG453 | Novartis | + Spartalizumab | I/II | NCT02608268 |
| OX40 agonists | |||||
| GSK3174998 | GlaxoSmithKline | Alone/ with Pembrolizumab | I | NCT02528357 | |
| MEDI-0562 | MedImmune | – | I | NCT02318394 | |
| MEDI-6383 (OX40L-Fc) | MedImmune | Alone/with MEDI-4736 | I | NCT02221960 | |
| PF-04518600 | Pfizer | Alone/with PF-05082566 | I | NCT02315066 | |
| MEDI-6469 | MedImmune | +Radiation | I | NCT01862900 | |
| BMS-986178 | Bristol-Myers Squibb | Alone/ with nivolumab ± ipilimumab | I/II | NCT02737475 | |
| ABBV-368 | Idera Pharmaceuticals | +ABBV-927 ± budigalimab | I | NCT03893955 | |
| GITR agonist | |||||
| INCAGN01876 | Incyte | Nivolumab and/ or ipilimumab | I/II | NCT03126110 | |
| INCAGN01876 | Incyte | Pembrolizumab and/ or epacadostat | I/II | NCT03277352 | |
| TRX518 | Leap Therapeutics | + Cyclophosphamide +/or Avelumab | I/II | NCT03861403 | |
| 4-1BB agonist | PF-05082566 (Utolimumab) | Pfizer | + Trastuzumab – Emtansine | I | NCT03364348 |
| PRS-343 | Pieris Pharmaceuticals, Inc. (PIRS) | +Atezolizumab | Ib | NCT03650348 | |
| CD40 agonist | CDX-1140 | Celldex Therapeutics | Alone or with Pembrolizumab | I | NCT03329950 |
| ICOS agonist | JTX-2011 | Jounce Therapeutics | Nivolumab/Ipilimumab/ Pembrolizumab | I/II | NCT02904226 |
| IDO1 inhibitor | |||||
| Indoximod | NewLink Genetics | - | I | NCT00739609 | |
| +Docetaxel/paclitaxel | II | NCT01792050 | |||
| Epacadostat | Incyte Corporation | + INCMGA00012 and Epacadostat | I/II | NCT03328026 | |
| +/or Itacitinib with INCB050465 | I | NCT02559492 | |||
| Targeting Arginase-1 | Arginase-1 peptide vaccine | IO Biotech ApS. | I | NCT03689192 | |
| CXCR4 antagonist | balixafortide | Polyphor | +Eribulin | III | NCT03786094 |
| CCR5 antagonist | Leronlimab | CytoDyn, Inc. | - | - | NCT04313075 |
| CD73 antagonists | ±Oleclumab (MEDI9447) | IMFINZI® | + Carboplatin + Paclitaxel +Durvalumab | I/II | NCT03616886 |
| CPI-006 | Corvus Pharmaceuticals | Alone/ with Ciforadenant +Pembrolizumab | I | NCT03454451 | |
| A2AR antagonist | CPI-444 Ciforadenant | Corvus Pharmaceuticals | Alone/ with Combination+ Atezolizumab | I | NCT02655822 |
| PGEP4R blocker | AAT-007 | Applied Therapeutics | - | II | NCT02538432 |
| CSF1R blocker | LY3022855 | Imclone Llc | Alone/ with Durvalumab or Tremelimumab | I | NCT02718911 |
| Pexidartinib (PLX-3397) | Daiichi Sankyo | + Eribulin | I/II | NCT01596751 | |
| Emactuzumab (RG7155) | Roche | +Atezolizumab | NCT02323191 | ||
| +RG7876 | I | NCT02760797 | |||
| VEGFR blocker | Ramucirumab | Eli Lilly and Company | +Docetaxel | III | NCT00703326 |
| Lucitanib | Clovis Oncology, Inc. | – | II | NCT02202746 | |
| TLR7 agonist | 852A | Pfizer | – | II | NCT00319748 |
| Imiquimod | NYU Langone Health | – | II | NCT00899574 | |
| STING agonist | ADU-S100 (MIW815) | Novartis Pharmaceuticals | +Spartalizumab | I | NCT03172936 |
| E7766 | Eisai Inc. | - | I | NCT04144140 |